Industry News
Eyerising Myopia Management Device Listed in ARTG
A significant advancement in myopia control therapy has been introduced with Eyerising Myopia Management Device, the world-first at-home device for Myopia control. Designed specifically for children aged between 3 and 16 years old, this innovative device aims to address the growing concerns around myopia progression. Eyerising Myopia Management Device is a product of Eyerising International, a company that is leading the effort to control the progression of childhood Myopia. The Eyerising Myopia Management Device is already approved for sale in Europe and recently it gained listing in the Australian Register of Therapeutic Goods (ARTG No: 41275).
The Eyerising Myopia Management Device utilises patented technology, delivering Repeated Low-Level Red-Light (RLRL) therapy. By gently stimulating blood flow in the ocular fundus, the device seeks to alleviate sclera hypoxia and control axial lengthening, which are known causes of myopia.
One of the key advantages of this therapy is its convenience. Children can use the device at home, under parental supervision, for just 3 minutes, twice a day, on 5 days a week, with a minimum 4-hour interval between sessions. This therapy approach offers potential benefits for managing myopia earlier and provides additional treatment options for clinicians. Moreover, the Eyerising Myopia Management Device comes with a simple touchscreen control, making it suitable for use by children as young as 3 years old.
Patient compliance is monitored and data is shared with practitioners during follow-up examinations. This feature empowers healthcare professionals to tailor treatment plans according to individual patient needs.
It's essential to note that the inclusion of this device in the ARTG adheres to the conditions set forth in the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002.
With this latest development, the Eyerising Myopia Management Device brings hope to parents, guardians, and practitioners seeking effective and accessible myopia control solutions for children. As more information becomes available, interested parties can approach local practitioners or refer to the official website for further details on this promising breakthrough in myopia management therapy.